A 42-year-old woman from Odisha presents with a single well-demarcated hypopigmented patch on her left arm with complete loss of sensation and absent sweating over the lesion. She has no palpable nerve thickening. Slit-skin smear from the lesion is negative for acid-fast bacilli. She has no systemic symptoms. What is the most appropriate next step in management?

Explanation

## Management of Paucibacillary (Tuberculoid) Leprosy This patient has **tuberculoid leprosy (TT)**, the paucibacillary form, and requires **6-month MDT with counseling on self-care and monitoring**. ### Diagnostic Features of Tuberculoid Leprosy | Feature | Finding | Significance | |---------|---------|---------------| | Number of lesions | Single or few (≤5) | Paucibacillary | | Lesion morphology | Well-demarcated, hypopigmented | Characteristic of TT | | Sensory loss | Complete within lesion | Indicates strong CMI | | Sweating | Absent over lesion | Anhidrosis is pathognomonic | | Nerve involvement | Absent/minimal | No palpable nerve thickening | | Slit-skin smear | Negative (BI 0–1) | Paucibacillary; <5 bacilli | | Lepromin test | Positive (Type IV hypersensitivity) | Strong cell-mediated immunity | ### Why This Is Tuberculoid Leprosy **High-Yield:** Tuberculoid leprosy is defined by: 1. **Single or few lesions** (≤5) ✓ 2. **Negative or very low bacillary index** (slit-skin smear negative) ✓ 3. **Complete sensory loss within lesion** ✓ 4. **Anhidrosis (absent sweating)** ✓ 5. **Minimal or no nerve involvement** ✓ 6. **Strong cell-mediated immunity** (positive lepromin test) **Key Point:** The **absence of nerve palpability** in a patient with a single lesion and negative slit-skin smear is diagnostic of TT, not borderline forms. ### MDT Regimen for Paucibacillary Leprosy **Mnemonic: RDC-6 (Rifampicin, Dapsone, Clofazimine × 6 months)** ```mermaid flowchart TD A[Tuberculoid Leprosy Diagnosed]:::outcome --> B[6-Month MDT Regimen]:::action B --> C[Rifampicin 600 mg monthly supervised]:::action B --> D[Dapsone 100 mg daily unsupervised]:::action B --> E[Clofazimine 50 mg daily + 300 mg monthly]:::action C --> F[Complete 6 doses = cure]:::outcome D --> F E --> F F --> G[Counsel on self-care & monitoring]:::action ``` ### Essential Counseling & Self-Care **Clinical Pearl:** Even though the patient is paucibacillary and has minimal bacterial load, **self-care counseling is critical** to prevent disability from the existing nerve damage and sensory loss. **Key Point:** Self-care includes: - **Foot care:** Regular inspection, protective footwear, avoid trauma - **Hand care:** Protect hands during work; avoid burns - **Eye care:** If facial lesion, check for lagophthalmos - **Compliance:** Complete 6-month MDT without interruption - **Follow-up:** Monthly clinic visits during treatment; assess for Type 1 reactions ### Why Not the Other Options? **Warning:** Common mistakes in paucibacillary leprosy management: 1. **12-month MDT (lepromatous regimen):** Tuberculoid leprosy is paucibacillary and requires only **6 months**, not 12. The longer regimen is reserved for multibacillary forms (BT, BB, BL, LL). 2. **Nerve conduction studies before treatment:** Not indicated. Clinical diagnosis is sufficient; NCS would delay essential treatment. NCS is useful for assessing nerve damage severity **after diagnosis**, not for diagnosis itself. 3. **Observation for 3 months:** Leprosy is a **notifiable disease** and requires prompt treatment to prevent transmission and disability. Delaying treatment is not recommended and increases risk of nerve damage progression. ### Monitoring During & After Treatment **High-Yield:** Watch for **Type 1 lepra reaction (reversal reaction)**: - Can occur during or up to 1 year after treatment - Presents with acute inflammation of lesions and nerve pain - Managed with corticosteroids (prednisolone 0.5–1 mg/kg/day) - More common in borderline forms (BT, BB, BL) but can occur in TT